US Patent 7553829 Treatment of chronic fatigue syndrome and fibromyalgia syndrome
All edits
Edits on 15 Sep, 2023
Golden AI
Edits made to:
Article (+186 characters)
Article
Patent abstract
Chronic fatigue syndrome (CFS) and fibromyalgia syndrome (FMS) can be treated by the administration of Δ5-androstene-3β-ol-7,17 dione and metabolizable precursors thereof.
Edits on 25 May, 2023
Golden AI
Edits made to:
Infobox (-1 properties)
Infobox
Official Website
Edits on 21 May, 2023
Golden AI
Edits made to:
Infobox (+1/-1 properties)
US Patent 07553829 Treatment of chronic fatigue syndrome and fibromyalgia syndrome US Patent 7553829 Treatment of chronic fatigue syndrome and fibromyalgia syndrome
Infobox
Patent Number
0755382900
Patent Number
755382900
Edits on 24 Mar, 2023
Golden AI
Infobox
Is a
Patent Jurisdiction
Patent Number
075538290
Date of Patent
June 30, 2009
0Patent Application Number
104330430
Date Filed
October 31, 2001
0Official Website
Patent Primary Examiner
Edits on 23 Sep, 2022
Golden AI
Infobox
Is a
Patent Jurisdiction
Patent Number
075538290
Date of Patent
June 30, 2009
0Patent Application Number
104330430
Date Filed
October 31, 2001
0Official Website
Patent Primary Examiner
Edits on 18 Jun, 2022
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Website URL
Edits on 2 Dec, 2021
Golden AI
Edits made to:
Infobox (+7 properties)
US Patent 07553829 Treatment of chronic fatigue syndrome and fibromyalgia syndrome
Infobox
Is a
Patent jurisdiction
Patent number
07553829
Date of patent
June 30, 2009
Patent application number
10433043
Date Filed
October 31, 2001
Patent primary examiner
Find more entities like US Patent 7553829 Treatment of chronic fatigue syndrome and fibromyalgia syndrome
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
By using this site, you agree to our Terms of Service.